Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.
Antoine BachelardQuentin Le HingratValentine-Marie FerréMinh LêGilles PeytavinFlorence DamondCharlotte CharpentierGuillemette Fremont GoudotJeanne Goupil de BouilleSylvie LarivenPierre DelobelYazdan YazdanpanahDiane DescampsSophie MatheronJade Ghosnnull nullPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2024)
We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
Keyphrases
- human immunodeficiency virus
- multidrug resistant
- antiretroviral therapy
- hiv infected
- hepatitis c virus
- hiv positive
- drug resistant
- acinetobacter baumannii
- hiv aids
- gram negative
- hiv infected patients
- klebsiella pneumoniae
- placebo controlled
- hiv testing
- randomized controlled trial
- pseudomonas aeruginosa
- south africa
- escherichia coli